2023 年第 12 期 第 18 卷

奥美拉唑联合FOLFOX6化疗方案对结肠癌术后患者的疗效研究

Efficacy of omeprazole combined with FOLFOX6 chemotherapy on postoperative colon cancer patients

作者：黄洋

英文作者：Huang Yang

单位：辽宁中医药大学附属第三医院痔瘘三科，沈阳110003，Email:ihihfd_6762@163.com

英文单位：The Third Department of Hemorrhoid Fistula the Third Affiliated Hospital of Liaoning University of Traditional Chinese Medicine Shenyang 110003 China Email: ihihfd_6762@163.com

关键词：结肠癌；奥美拉唑；FOLFOX6化疗方案；液泡型三磷酸腺苷酶蛋白

英文关键词：Coloncancer;Omeprazole;FOLFOX6chemotherapyplan;Vacuolar-typeATPaseprotein

• 摘要：

• 目的  探究奥美拉唑联合奥沙利铂+亚叶酸钙+5-氟尿嘧啶（FOLFOX6）化疗方案对结肠癌术后患者的疗效。方法  选取2017年7月至2019年8月辽宁中医药大学附属第三医院收治的结肠癌患者80例，按术后治疗方案不同分为对照组和观察组，各40例。对照组患者根治性手术后采用FOLFOX6方案化疗，观察组术后采用FOLFOX6化疗方案联合奥美拉唑治疗。治疗结束后对患者进行3年随访。比较2组化疗6~8个疗程后客观缓解率（ORR），液泡型三磷酸腺苷酶（V-ATPase）蛋白阳性表达率，患者术后1、2、3年无进展生存率，2组不同V-ATPase蛋白表达状况患者的1、2、3年无进展生存率以及不良反应发生情况。结果  观察组患者的ORR高于对照组［65.0%（26/40）比37.5%（15/40）］（P=0.014）。2组患者V-ATPase蛋白阳性率比较差异无统计学意义（P＞0.05）。观察组患者术后1、2、3年无进展生存率均明显高于对照组［82.5%（33/40）比57.5%（23/40）、70.0%（28/40）比45.0%（18/40）、47.5%（19/40）比25.0%（10/40）］（均P＜0.05）。对照组中，V-ATPase蛋白阳性者1、2、3年无进展生存率和V-ATPase蛋白阴性者比较差异均无统计学意义（均P＞0.05）；但观察组中，V-ATPase蛋白阳性者1、2、3年无进展生存率均高于V-ATPase蛋白阴性者（均P＜0.05）。2组患者不良反应发生率比较差异均无统计学意义（均P＞0.05）。结论  奥美拉唑联合FOLFOX6化疗方案不仅能够提高结肠癌患者手术后的近期疗效，而且能够提高V-ATPase蛋白阳性表达结肠癌患者1~3年的远期疗效。

• Objective To investigate the effects of omeprazole combined with oxaliplatin+folinic acid+5-fluorouracil (FOLFOX6) chemotherapy regimen on postoperative colon cancer patients. Methods Totally 80 patients with colon cancer admitted to the Third Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from July 2017 to August 2019 were collected. They were divided into the control group and the observation group according to the treatment plan, with 40 cases in each group. The control group was treated with FOLFOX6 chemotherapy plan, and the observation group was treated with omeprazole on the basis of FOLFOX6 chemotherapy plan. After treatment, patients were followed-up for 3 years. The objective  response rate (ORR) after 6-8 courses of chemotherapy, the expression of Vacuolar-type ATPase (V-ATPase) protein, the 1, 2 and 3-year progression free survival rate, the 1, 2 and 3-year progression free survival rate of patients with different status of V-ATPase protein expression and occurrence of adverse reactions were compared between the two groups. Results  The ORR of the observation group was higher than that of the control group ［65.0%(26/40) vs 37.5%(15/40)］(P=0.014). There was no statistically significant difference in the positive rate of V-ATPase protein between the two groups(P＞0.05). The observation group had significantly higher progression free survival rates at the 1, 2 and 3-year after surgery compared to the control group ［82.5%(33/40) vs 57.5%(23/40), 70.0%(28/40) vs 45.0%(18/40), 47.5%(19/40) vs 25.0%(10/40)］(all P＜0.05). In the control group, there was no statistically significant difference in the 1, 2, 3-year progression free survival rate between V-ATPase protein positive individuals and V-ATPase protein negative individuals (all P＞0.05); however, in the observation group, the 1, 2 and 3-year progression free survival rates of V-ATPase protein positive individuals were higher than those of V-ATPase protein negative individuals (all P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(all P＞0.05). Conclusion Omeprazole combined with FOLFOX6 chemotherapy scheme can not only improve the ORR of colon cancer patients after surgery, but also improve the effect of colon cancer patients with positive expression of V-ATPase protein for 1-3 years.